1432044-45-5Relevant academic research and scientific papers
Amino Acid Ligands for Ruthenium(II)-Catalyzed C–H Arylation of Aryltetrazoles with Chlorides: Expedient Access to Antihypertension Drugs
Hubrich, Jonathan,Ackermann, Lutz
, p. 3700 - 3704 (2016)
Versatile ruthenium(II) complexes derived from amino acids enabled the first general C–H arylations of aryltetrazoles with inexpensive aryl chlorides. The user-friendly Piv-Val-OH-based ruthenium(II) catalyst was characterized by a broad substrate scope, excellent functional group tolerance, and high catalytic activity. Thereby, the ruthenium(II) catalysis set the stage for the step-economical preparation of the blockbuster antihypertension drug Valsartan, while displaying unique robustness in the C–H arylation regime.
Carboxylate-assisted ruthenium(II)-catalyzed C-H arylations of 5-aryl tetrazoles: Step-economical access to Valsartan
Diers, Emelyne,Phani Kumar,Mejuch, Tom,Marek, Ilan,Ackermann, Lutz
, p. 4445 - 4453 (2013/06/27)
Carboxylate assistance was key to success for highly efficient ruthenium-catalyzed direct ortho-arylations of tetrazolyl-substituted arenes with aryl halides and triflates in the absence of phosphine ligands. Thus, ruthenium(II) biscarboxylates allowed for C-H bond functionalizations with excellent chemo- and site-selectivities, which set the stage for an atom- and step-economical access to key angiotensin-II-receptor blockers. Mechanistic studies revealed the C-H bond metalation to be reversible, and were suggestive of a rate-determining reductive elimination.
